Suchergebnisse - "Ciliberto, Domenico"

PubPharm (35)

1

Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients : Case series of mono-institutional experience

enthalten in: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | 2024

von Staropoli, N. | Scionti, F. | Farenza, V. | +15

2

Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma

enthalten in: International journal of molecular sciences | 2024

von Giannitrapani, L. | Di Gaudio, F. | Cervello, M. | +18

3

The Italian Rare Biliary tract Cancer initiative (IRaBiCa) : A multicentric observational study of Gruppo Oncologico dell'Italia Meridionale (GOIM) in collaboration with Gruppo Italiano Colangiocarcinoma (GICO)

enthalten in: Tumori | 2024

von Speranza, D. | Sapuppo, E. | Aprile, G. | +34

4

The impact of PARP inhibitors in the whole scenario of ovarian cancer management : A systematic review and network meta-analysis

enthalten in: Critical reviews in oncology/hematology | 2024

von Staropoli, N. | Ciliberto, D. | Luciano, F. | +13

5

First-line systemic treatment for hepatocellular carcinoma : A systematic review and network meta-analysis

enthalten in: Heliyon | 2023

von Ciliberto, D. | Caridà, G. | Staropoli, N. | +8

6

Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients : a first-in-human, phase 1, open-label, dose-escalation study

enthalten in: Journal of hematology & oncology | 2023

von Tassone, P. | Di Martino, M. | Arbitrio, M. | +21

7

Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study

enthalten in: Journal of hematology & oncology | 2023

von Tassone, P. | Di Martino, M. | Arbitrio, M. | +21

8

Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study

enthalten in: Journal of hematology & oncology | 2023

von Tassone, P. | Di Martino, M. | Arbitrio, M. | +21

9

Pembrolizumab plus lenvatinib in advanced endometrial cancer : case report and systematic review of lung toxicity

enthalten in: Frontiers in oncology | 2023

von Staropoli, N. | Salvino, A. | Falcone, F. | +10

10

A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer : A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics

enthalten in: Biomedicines | 2022

von Staropoli, N. | Arbitrio, M. | Salvino, A. | +12